Relatlimab / Nivolumab Improves TFI and PFS2 in Frontline Advanced Melanoma
Source: OncLive, September 2021
The addition of relatlimab to nivolumab (Opdivo) prolonged benefit beyond initial treatment and first progression and reduced the risk of progression or death after the next line of systemic therapy vs nivolumab alone in previously untreated patients with metastatic or unresectable melanoma, according to additional data from the phase 2/3 RELATIVITY-047 trial (NCT03470922).1
